NCT05126862

Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3)

Completed NA Results posted Last updated 20 December 2024

What this trial tests

NA trial testing MindTrails in Huntington Disease in 43 participants. Completed in 9 July 2023.

Timeline

10 December 2021

Primary endpoint
9 July 2023

9 July 2023

Quick facts

Lead sponsor	University of Virginia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	10 December 2021
Primary completion	9 July 2023
Estimated completion	9 July 2023
Sites	1 location across United States

Drugs / interventions tested

• MindTrails

Conditions studied

• Huntington Disease — all drugs for Huntington Disease →
• Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

University of Virginia

Who can join

21 and older, any sex, with Huntington Disease or Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Proportion of Participants Completing at Least 50% of the MindTrails Sessions Primary · Between baseline and week 5

Proportion of participants completing at least 50% of the MindTrails sessions (defined as proportion of participants who completed outcome assessments for at least 2 of the 3 timepoints measured during the intervention: baseline, week 3, and week 5)

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	14
Experimental: MindTrails Pilot in Huntington's Disease	14

Participant Perceptions of Perceived Benefits and Limitations of MindTrails Primary · After completion of the intervention (week 5)

All participants in each arm were invited to complete a semi-structured interview to assess their experience with the intervention or barriers to beginning or completing the intervention. Interviews were transcribed, and separate codebooks were developed for PD and HD transcripts. Each transcript was coded by 2 coders, and any disagreements were resolved by a third coder. Frequency of overlapping codes under the "Experiences completing MindTrails" theme for each group (PD and HD) are reported here.

did not need help to complete

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	12
Experimental: MindTrails Pilot in Huntington's Disease	9

needed caregiver assistance

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	1
Experimental: MindTrails Pilot in Huntington's Disease	1

completed it on phone

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	3
Experimental: MindTrails Pilot in Huntington's Disease	1

completed on computer

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	3
Experimental: MindTrails Pilot in Huntington's Disease	3

participant baseline characteristics influence experience positively

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	4
Experimental: MindTrails Pilot in Huntington's Disease	4

participant baseline characteristics influence experience negatively

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	4
Experimental: MindTrails Pilot in Huntington's Disease	5

positive experience/ enjoyed MindTrails

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	7
Experimental: MindTrails Pilot in Huntington's Disease	4

easy to navigate/ straight-forward

Group	Value	95% CI
Experimental: MindTrails Pilot in Parkinson's Disease	13
Experimental: MindTrails Pilot in Huntington's Disease	10

Sponsor's own description

The purpose of this study is conduct a pilot open trial of a web-based cognitive bias modification intervention to reduce anxiety symptoms in persons with Huntington's disease and persons with Parkinson's disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.